Journal of Clinical & Experimental Dermatology Research
Open Access
ISSN: 2155-9554
+44 1478 350008
ISSN: 2155-9554
+44 1478 350008
Lazaros I Sakkas, Christos Liaskos, Eleni Patrikiou, Efterpi Zafiriou, Athanasios Gkoutzourelas, Thomas Scheper, Wolfgang Meyer, Aggeliki RoussakiSchulze, Ioannis Alexiou and Dimitrios P Bogdanos
University of Thessaly, Greece
Institute of Experimental Immunology-EUROIMMUN AG, Germany
Scientific Tracks Abstracts: J Clin Exp Dermatol Res
Introduction: Antinuclear antibodies (ANAs) may be detected in psoriatic arthritis (PsA) and psoriasis (Ps) but the antigenspecificities have not been defined. International Consensus on ANA patterns (ICAP) has reported 14 ANA immunofluorescence (IF) patterns and commercial molecular-based multiplex assays were developed to assist ICAPâ�?�?s IF ANA testing. Aim: To identify ANA specificities in Ps and PsA using a recently developed multiplex immunoassay specifically designed for ANA. Material & Methods: A total of 70 patients (38 female) with Ps (n=36) or PsA (n=34) and 50 demographically matched normal controls (NCs) were tested by an ANA line immunoassay containing 23 different antigens: dsDNA, nucleosomes, histones, SS-A, Ro-52, SS-B, nRNP/Sm, Sm, Mi-2�?±, Mi-2�?², Ku, CENP A, CENP B, Sp100, PML, Scl-70, PM-Scl100, PM-Scl75, RP11, RP155, gp210, PCNA and DFS70. Results: Overall, reactivity to at least 1 against antigen was found in 23/70 patients (32.9%) compared to 6/50 (12%) NCs (p=NS; Ps vs PsA, p=NS). Specifically, the ICAP-related abs in Ps/PsA patients were as follows: AC-1:4.3%; AC-2:10%; AC-3:0.7%; AC-4:11.4%; AC-5:0.7%; AC-6:0.7%; AC-8:2.8%, and AC-10: 2.1%, while in NCs ICAP-related abs were as follows: AC-2:4%; AC-4:4%, AC-3:2%; AC-8:2% and AC-11:2% pattern. There was no statistically difference for the presence of ICAP between Ps and PsA and between Ps/ PsA and NCs. Conclusion: Testing for ANA specificities does not reveal a dominant ANA target in PsA and Ps.
Lazaros I Sakkas is currently working as a Professor of Medicine and Rheumatology, Chairman of Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly. He is also an Adjunct Assistant Professor at Temple University School of Medicine, Philadelphia, PA, USA (Jun 2003to till date) and has worked as an Adjunct Professor at Center for Molecular Medicine, Old Dominion University, Norfolk, VA, USA (2010-2017). He is the President at the Institute for Rheumatic Diseases (2011 to till date) and Co-Editor of the Mediterranean Journal of Rheumatology.
Email:lsakkas@med.uth.gr